Puma Biotechnology (PBYI) Total Liabilities (2011 - 2026)

Puma Biotechnology's Total Liabilities history runs 16 years deep, the most recent figure standing at $64.3 million for Q1 2026.

• Quarterly Total Liabilities fell 35.12% year-over-year to $64.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $64.3 million (down 35.12% YoY) and the FY2025 annual result came in at $86.0 million, down 29.08% from the prior year.
• Total Liabilities was $64.3 million for Q1 2026 at Puma Biotechnology, down from $86.0 million in the prior quarter.
• Across five years, Total Liabilities topped out at $200.5 million in Q4 2022 and bottomed at $64.3 million in Q1 2026.
• A 5-year average of $143.8 million and a median of $163.2 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities dropped 2.2% — and 2025, when it plunged 42.36%.
• Puma Biotechnology's Total Liabilities stood at $200.5 million in 2022, then dropped by 11.66% to $177.1 million in 2023, then tumbled by 31.55% to $121.2 million in 2024, then fell by 29.08% to $86.0 million in 2025, then decreased by 25.22% to $64.3 million in 2026.
• Business Quant data shows PBYI's Total Liabilities at $64.3 million in Q1 2026, $86.0 million in Q4 2025, and $87.6 million in Q3 2025.